Evidence map›Paper›PMID 41254633›Full record

ReviewBMC pulmonary medicine2025

Pulmonary mucormycosis complicated by necrotizing pneumonia secondary to an obstructive endobronchial tumor-like lesion: a case report and review of literature.

Ngoc Duong-Minh, Khoa Nguyen-Dang

Abstract readCase ReportsReview
In one paragraph

Review in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ngoc Duong-MinhUniversity Medical Center Ho Chi Minh City, Ho Chi Minh City, Viet Nam.
Khoa Nguyen-DangDepartment of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. nguyendangkhoa@ump.edu.vn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMucormycosis is a rare but life-threatening invasive fungal infection, most commonly affecting immunocompromised individuals, especially those with poorly controlled diabetes mellitus. Pulmonary mucormycosis (PM) represents the second most frequent clinical form after rhino-orbital-cerebral disease and carries a high mortality rate. Diagnosis is often delayed because its clinical and radiological manifestations overlap with other pulmonary infections and malignancies. Necrotizing pneumonia secondary to endobronchial mucormycosis is exceptionally rare, representing a distinct and severe form of pulmonary involvement, with only sporadic cases reported in the literature. CASE PRESENTATION: A 71-year-old female farmer with previously undiagnosed and poorly controlled diabetes presented with progressive dyspnea, fever, productive cough, and weight loss. Initial chest computed tomography demonstrated necrotizing pneumonia in the right lower lobe. Broad-spectrum antibiotics failed to improve her condition, and cultures for bacteria, fungi, and Mycobacterium tuberculosis were negative. Flexible bronchoscopy revealed an endobronchial mass with whitish pseudomembranes nearly occluding the right lower lobe bronchus. Biopsy was complicated by profuse bleeding, which was controlled with local adrenaline. Histopathological examination confirmed endobronchial mucormycosis with extensive tissue necrosis, and intravenous amphotericin B was promptly initiated. The patient was later transitioned to oral posaconazole, resulting in gradual clinical and radiological improvement. Follow-up imaging at three and six months demonstrated complete resolution.

conclusionThis case illustrates a rare presentation of necrotizing pneumonia secondary to endobronchial mucormycosis in a diabetic patient. Histopathological confirmation remains essential for diagnosis, particularly in patients presenting with necrotizing pneumonia and mass-like airway lesions unresponsive to antibiotics. Early recognition, timely antifungal therapy, and prolonged follow-up with serial imaging are critical to achieving full recovery and preventing recurrence.

Indexed as

Lung Diseases, FungalMucormycosisPneumonia, NecrotizingAgedAmphotericin BAntifungal AgentsBronchoscopyFemaleHumansTomography, X-Ray ComputedTriazolesAmphotericin BAntifungal AgentsposaconazoleTriazolesDiabetesEndobronchial tumorNecrotizing pneumoniaPulmonary mucormycosis

Identifiers

PMID41254633
PMCPMC12625637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.